ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. B+L Bolsters Ophthalmology With Acquis
Generics BulletinHikma’s CEO Riad Mishlawi must have been on a good list as his wish to get US approval for the firm’s generic liraglutide around Christmas came true. The US Food and Drug Administration approved the g
ScripIn its latest effort to identify drugs with price increases that had the biggest impact on US health care spending, the Institute for Clinical and Economic Review (ICER) included Merck & Co.’s Key
Generics BulletinHikma Pharmaceuticals is in the midst of a shift in its research and development strategy that will prioritize fewer but higher-value products over a larger number of drugs that represent smaller-scal